Recombinant Anti-CCR3 x Anti-CD300 Bispecific Antibody (scFv-IgG) is formed by an IgG and two scFv fragments. The scFvs from an anti-CCR3 antibody variable domain are respectively connected to the N terminus of the anti-CD300 IgG heavy chains or light chains to form scFv-(H)IgG or scFv-(L)IgG. It is a type of appended IgGs and has 2+2 antigen-binding valency. This BsAb canreduce eosinophil signaling, inhibit bronchoalveolar lavage fluid inflammation, eosinophil, mast cell mediator release and reverse lung inflammation. It is designed for the research of Asthma therapy.